Dr Lal, Metropolis, Thyrocare beat the Nifty 50. Litmus test: sustaining growth after the pandemic.

The spike in the demand for diagnostic tests has sent the shares of the three listed players soaring. While Covid-19 test volumes and realisations of these companies are expected to be volatile, such tests will remain a key part of their business in the foreseeable future. Is this merely a rally driven by a resurgent virus, or does it mark a watershed moment for these companies and the sector?

You may also like...

Leave a Reply

Your email address will not be published. Required fields are marked *